{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    11,
    12,
    13,
    19,
    28,
    34,
    37,
    39,
    40,
    41,
    42,
    44,
    46,
    52,
    54
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Safety and Management Guidelines",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.2.2.2",
        "sectionTitle": "Safety of Atezolizumab Monotherapy",
        "description": "Reference to immune-mediated events associated with atezolizumab"
      },
      {
        "id": "ref_2",
        "name": "Safety and Management Guidelines",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1.2",
        "sectionTitle": "Potential Risks for Atezolizumab",
        "description": "Reference to immune-mediated events and potential risks"
      },
      {
        "id": "ref_3",
        "name": "Safety and Management Guidelines",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1.4",
        "sectionTitle": "Management Guidelines",
        "description": "Reference to management of immune-mediated events"
      },
      {
        "id": "ref_4",
        "name": "Dose Modifications",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1.5.3.2",
        "sectionTitle": "Paclitaxel Dose Modifications",
        "description": "Details on paclitaxel dose modifications due to toxicity"
      },
      {
        "id": "ref_5",
        "name": "Adverse Events of Special Interest",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.2.3",
        "sectionTitle": "Adverse Events of Special Interest",
        "description": "List of adverse events of special interest"
      },
      {
        "id": "ref_6",
        "name": "Schedule of Activities",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 1",
        "sectionTitle": "Schedule of Activities",
        "description": "Internal link to the study schedule of activities"
      },
      {
        "id": "ref_7",
        "name": "Management Guidelines",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 11",
        "sectionTitle": "Risks Associated with Atezolizumab",
        "description": "Guidelines for management of adverse events associated with atezolizumab"
      },
      {
        "id": "ref_8",
        "name": "Study Schema",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Figure 1",
        "sectionTitle": "Study Schema",
        "description": "Visual representation of the study design"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "To align with the Atezolizumab Investigator's Brochure, Version 15, 'immune-related' has been changed to 'immune-mediated' when describing events associated with atezolizumab.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Rationale",
        "pageNumber": 3
      },
      {
        "id": "annot_2",
        "text": "Serum pharmacokinetic/anti-drug antibody samples have been removed at Follow-Up in Appendix 1 as the assessment was already discontinued as of Protocol MO39196, Version 3.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Rationale",
        "pageNumber": 3
      },
      {
        "id": "annot_3",
        "text": "Because the effects of corticosteroids on T-cell proliferation have the potential to ablate early atezolizumab-mediated anti-tumour immune activity, it is recommended that the dose of dexamethasone is minimised.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Paclitaxel (Background Chemotherapy)",
        "pageNumber": 29
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "1.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-02-14",
        "description": "Initial Protocol",
        "amendmentNumber": "Original"
      },
      {
        "id": "ver_2",
        "versionNumber": "2.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-05-12",
        "description": "Amended Protocol",
        "amendmentNumber": "Amendment 1"
      },
      {
        "id": "ver_3",
        "versionNumber": "3.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-12-05",
        "description": "Amended Protocol",
        "amendmentNumber": "Amendment 2"
      },
      {
        "id": "ver_4",
        "versionNumber": "4.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2018-12-17",
        "description": "Amended Protocol",
        "amendmentNumber": "Amendment 3"
      },
      {
        "id": "ver_5",
        "versionNumber": "5.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2019-05-23",
        "description": "Amended Protocol",
        "amendmentNumber": "Amendment 4"
      },
      {
        "id": "ver_6",
        "versionNumber": "6.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-02-11",
        "description": "Protocol Amendment 6 incorporating updates to risks and management guidelines",
        "amendmentNumber": "Amendment 5"
      }
    ],
    "summary": {
      "referenceCount": 8,
      "annotationCount": 3,
      "versionCount": 6
    }
  }
}